TY - JOUR
T1 - Plasmodium vivax sporozoite challenge in malaria-naïve and semi-immune Colombian volunteers
AU - Arévalo-Herrera, Myriam
AU - Forero-Peña, David A.
AU - Rubiano, Kelly
AU - Gómez-Hincapie, José
AU - Martínez, Nora L.
AU - Lopez-Perez, Mary
AU - Castellanos, Angélica
AU - Céspedes, Nora
AU - Palacios, Ricardo
AU - Oñate, José Millán
AU - Herrera, Sócrates
PY - 2014/6/25
Y1 - 2014/6/25
N2 - Background: Significant progress has been recently achieved in the development of Plasmodium vivax challenge infections in humans, which are essential for vaccine and drug testing. With the goal of accelerating clinical development of malaria vaccines, the outcome of infections experimentally induced in naïve and semi-immune volunteers by infected mosquito bites was compared. Methods: Seven malaria-naïve and nine semi-immune Colombian adults (n = 16) were subjected to the bites of 2-4 P. vivax sporozoite-infected Anopheles mosquitoes. Parasitemia levels, malaria clinical manifestations, and immune responses were assessed and compared. Results: All volunteers developed infections as confirmed by microscopy and RT-qPCR. No significant difference in the prepatent period (mean 12.5 and 12.8 days for malaria-naïve and malaria-exposed, respectively) was observed but naïve volunteers developed classical malaria signs and symptoms, while semi-immune volunteers displayed minor or no symptoms at the day of diagnosis. A malaria-naïve volunteer developed a transient low submicroscopic parasitemia that cured spontaneously. Infection induced an increase in specific antibody levels in both groups. Conclusion: Sporozoite infectious challenge was safe and reproducible in semi-immune and naïve volunteers. This model will provide information for simultaneous comparison of the protective efficacy of P. vivax vaccines in naïve and semiimmune volunteers under controlled conditions and would accelerate P. vivax vaccine development. Trial Registration: clinicaltrials.gov NCT01585077
AB - Background: Significant progress has been recently achieved in the development of Plasmodium vivax challenge infections in humans, which are essential for vaccine and drug testing. With the goal of accelerating clinical development of malaria vaccines, the outcome of infections experimentally induced in naïve and semi-immune volunteers by infected mosquito bites was compared. Methods: Seven malaria-naïve and nine semi-immune Colombian adults (n = 16) were subjected to the bites of 2-4 P. vivax sporozoite-infected Anopheles mosquitoes. Parasitemia levels, malaria clinical manifestations, and immune responses were assessed and compared. Results: All volunteers developed infections as confirmed by microscopy and RT-qPCR. No significant difference in the prepatent period (mean 12.5 and 12.8 days for malaria-naïve and malaria-exposed, respectively) was observed but naïve volunteers developed classical malaria signs and symptoms, while semi-immune volunteers displayed minor or no symptoms at the day of diagnosis. A malaria-naïve volunteer developed a transient low submicroscopic parasitemia that cured spontaneously. Infection induced an increase in specific antibody levels in both groups. Conclusion: Sporozoite infectious challenge was safe and reproducible in semi-immune and naïve volunteers. This model will provide information for simultaneous comparison of the protective efficacy of P. vivax vaccines in naïve and semiimmune volunteers under controlled conditions and would accelerate P. vivax vaccine development. Trial Registration: clinicaltrials.gov NCT01585077
U2 - 10.1371/journal.pone.0099754
DO - 10.1371/journal.pone.0099754
M3 - Journal article
C2 - 24963662
AN - SCOPUS:84903521198
SN - 1932-6203
VL - 9
JO - PLoS ONE
JF - PLoS ONE
IS - 6
M1 - e99754
ER -
